Cancerresearchisbroken.Tofixit,werebuiltthesubstratefromfirstprinciples.
Twenty million new diagnoses a year. The science needed to help them already exists — locked behind paper walls and fragmented compute.
Composable, not closed
Every agent is open weight, replaceable, and verifiable. Fork the Critic, retrain the Designer, ship a custom Sentinel — all on the same substrate.
Read the specDecentralized, not gate-kept
A global mesh of researcher-run nodes settles every simulation. Reputation tokens flow back to whoever moved the field — not the journal.
Read the specPatient-first, not paper-first
Clinical co-design from day zero. Every candidate ships with provenance, drug-likeness, and a path to wet-lab validation.
Read the spec“We replaced six months of wet-lab triage with a 38-minute Helix run. The candidates that came out the other side were already de-risked.”
Researchers across 26 institutions and 9 DAOs run candidates through Helix every day — not because they have to, but because the alternative is a notebook and a wait list.
Three agents, one closed loop. From a target sequence to a vetted candidate in under 38 minutes — every step verifiable on-chain.
Physical proteomics
Tumor antigens, mutational landscapes, and patient-specific surfacing — pulled from PDB, AlphaFoldDB, and clinical caches as a typed graph.
Generative design
RFdiffusion + ESM-2 produce 10⁴ candidate scaffolds per hour. Each carries druggability, half-life, and synthesis cost annotations from birth.
Simulation & dock
100 ns molecular dynamics, full free-energy landscape, off-target screen, and on-chain provenance — all before a single drop hits a flask.
Aggregate, design, and simulate in one platform.
Manage candidate generation
Designer is the adaptive design core that combines diffusion-based scaffolding with a no-code agent interface — let ESM-2, RFdiffusion, and ProteinMPNN compose against any tumor antigen.
Explore DesignerFast to deploy. Easy to fork. Built to scale to a million simulations a day. Helix is open today — your candidate could be on-chain by tonight.
Composable by design, Helix adapts to the unique antigen landscape of each cancer family. One platform, every modality, every patient cohort.
Modules for every
research vector.
Antigen Discovery
Mine tumor proteomes against patient-specific HLA — surface targets that are druggable and unique.
Generative Design
RFdiffusion + ESM-2 produce 10⁴ scaffolds an hour, ranked by druggability and synthesis cost.
Molecular Dynamics
100ns GROMACS runs on every shortlist. Pose stability, RMSD, energy landscape — all returned.
Off-Target Screen
Adversarial decoy panel of 9k+ alternates. Catch the cross-reactivity before it costs a patient.
Synthesis Routes
Retrosynthesis with cost and feasibility scoring across 90M+ commercial reagents.
Reputation Mint
Every contributor — agent or human — gets credited on-chain when their work moves the field.
Provenance Ledger
Full audit trail to Arweave. Reproduce any candidate, any time, on any node.
Biosafety Sentinel
Dual-use screening before publication. Helix won't release what shouldn't exist.
Wet-Lab Bridge
Order synthesis from partnered CROs without leaving the platform — provenance attached.
Fast to deploy. Easy to fork. Built to scale.